VPC
Vestal Point Capital Portfolio holdings
AUM
$2.73B
1-Year Est. Return
128.57%
This Fund
S&P 500
1 Year Est. Return
+128.57%
AUM
$2.2B
AUM Growth
+$305M
(+16%)
Holding
95
Top Buys
| 1 | +$74.6M | |
| 2 | +$61.3M | |
| 3 | +$55.7M | |
| 4 |
DexCom
DXCM
|
+$51.4M |
| 5 |
Repligen
RGEN
|
+$48.6M |
Top Sells
| 1 | +$108M | |
| 2 | +$92.7M | |
| 3 | +$84M | |
| 4 |
uniQure
QURE
|
+$63.1M |
| 5 |
KalVista Pharmaceuticals
KALV
|
+$54.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Disc Medicine
IRON
$2.53B
| $33M | 1.5% |
500,000
+360,000
|
|
||
27
Nurix Therapeutics
NRIX
$1.64B
| $32.1M | 1.46% |
3,475,000
+1,475,000
|
|
||
28
Crinetics Pharmaceuticals
CRNX
$3.91B
| $31.2M | 1.42% |
750,000
-750,000
|
|
||
29
Celldex Therapeutics
CLDX
$2.07B
| $31.2M | 1.41% |
1,205,000
-545,000
|
|
||
30
Zymeworks
ZYME
$1.89B
| $30.1M | 1.37% |
1,765,000
+615,000
|
|
||
31
Danaher
DHR
$138B
| $29.7M | 1.35% |
150,000
+100,000
|
|
||
32
Revolution Medicines
RVMD
$19.6B
| $29.4M | 1.33% |
630,000
-570,000
|
|
||
|
RAPP
33
Rapport Therapeutics
RAPP
$1.41B
| $28.2M | 1.28% |
+950,000
|
|
||
34
Enliven Therapeutics
ELVN
$1.81B
| $23.7M | 1.08% |
1,160,000
+910,000
|
|
||
35
Geron
GERN
$1.04B
| $23.6M | 1.07% |
17,225,000
-6,550,000
|
|
||
|
BLTE
36
Belite Bio
BLTE
$6.85B
| $23.1M | 1.05% |
+312,500
|
|
||
37
Ultragenyx Pharmaceutical
RARE
$2.21B
| $22.6M | 1.02% |
+750,000
|
|
||
38
Vera Therapeutics
VERA
$2.87B
| $22.1M | 1% |
760,000
-2,340,000
|
|
||
39
Lexeo Therapeutics
LXEO
$526M
| $21.6M | 0.98% |
3,250,000
+21,839
|
|
||
40
Black Diamond Therapeutics
BDTX
$129M
| $21M | 0.95% |
5,550,000
-50,000
|
|
||
41
Day One Biopharmaceuticals
DAWN
$2.2B
| $18.9M | 0.86% |
2,675,000
-325,000
|
|
||
42
Solid Biosciences
SLDB
$637M
| $18.4M | 0.83% |
2,975,000
+1,470,000
|
|
||
43
Axsome Therapeutics
AXSM
$8.51B
| $18.2M | 0.83% |
+150,000
|
|
||
44
Taysha Gene Therapies
TSHA
$1.25B
| $18M | 0.82% |
5,500,000
+2,500,000
|
|
||
45
Apogee Therapeutics
APGE
$5.19B
| $16.9M | 0.77% |
+425,000
|
|
||
46
Savara
SVRA
$1.14B
| $14.3M | 0.65% |
4,015,000
-7,000,000
|
|
||
47
Bruker
BRKR
$5.57B
| $14.3M | 0.65% |
440,000
-60,000
|
|
||
48
Regeneron Pharmaceuticals
REGN
$81.6B
| $14.1M | 0.64% |
+25,000
|
|
||
|
49
uniQure
QURE
$1.14B
| $13.1M | 0.6% |
225,000
-3,475,000
|
|
||
|
BBNX
50
Beta Bionics
BBNX
$487M
| $11.9M | 0.54% |
600,000
+50,000
|
|